MOTS-c vs Humanin
MOTS-c and Humanin are both mitochondrial-derived peptides (MDPs) -- peptides encoded within mitochondrial DNA rather than nuclear DNA. This is a relatively recent discovery in biology, and both peptides are being studied for their roles in metabolic regulation and cellular protection.
Side-by-Side Comparison
| Category | MOTS-c | Humanin |
|---|---|---|
| Mechanism of action | Activates AMPK (AMP-activated protein kinase), the cellular energy sensor. Functions as an exercise mimetic, improving glucose metabolism, fat oxidation, and insulin sensitivity. Translocates to the nucleus to regulate gene expression. | Binds to multiple receptors including FPRL1 and BAX. Protects cells from apoptosis (programmed cell death), reduces oxidative stress, and improves insulin sensitivity. Acts as a cytoprotective peptide. |
| Primary research area | Metabolic syndrome, obesity, exercise physiology, type 2 diabetes. Studied as an exercise mimetic that activates metabolic pathways normally triggered by physical activity. | Neuroprotection (Alzheimer's research), cytoprotection, metabolic syndrome, aging. Studied for its ability to protect cells from stress-induced death. |
| Evidence level | Primarily preclinical. Published animal studies showing metabolic improvements. Human observational studies showing correlation between MOTS-c levels and metabolic health. First described by Lee et al. (2015). No human interventional trials completed. | Primarily preclinical. First mitochondrial-derived peptide discovered (Hashimoto et al., 2001). Published animal studies on neuroprotection and metabolism. Human observational studies linking levels to longevity. No human interventional trials completed. |
| Administration route | Subcutaneous injection in animal studies. | Subcutaneous or intraperitoneal injection in animal studies. |
| Typical research dosing | Animal studies: 5-15 mg/kg. Human dosing not established. Community protocols vary widely due to lack of clinical guidance. | Animal studies used varying doses. Human dosing not established. Both peptides lack standardized human protocols. |
| Key studies/evidence | Lee et al. (2015) — original discovery and AMPK activation. Kim et al. — exercise mimetic properties and metabolic regulation in mice. Observational human data linking MOTS-c levels to exercise capacity. | Hashimoto et al. (2001) — original discovery. Muzumdar et al. — metabolic effects in animal models. Observational data linking humanin levels to centenarian longevity. |
Can They Be Stacked?
Both target mitochondrial function but through different mechanisms -- MOTS-c via AMPK metabolic activation and Humanin via cytoprotection. Theoretically complementary for mitochondrial health. However, given that neither has established human dosing or safety data from clinical trials, combining two experimental mitochondrial peptides introduces unpredictable interactions. Proceed with significant caution.
Verdict
Both are frontier research peptides with fascinating biology but limited clinical evidence. MOTS-c is more metabolically focused (exercise mimetic, AMPK activation), while Humanin is more cytoprotective (anti-apoptotic, neuroprotective). Neither has completed human interventional trials, so both should be considered highly experimental. The science is promising but the evidence base for human use is still being established.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.